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Abstract 
Background: The clinical characteristics and outcomes of asymptomatic patients with paroxysmal or 
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persistent/permanent atrial fibrillation (AF) are largely unknown. 
Methods: The Fushimi AF Registry is a community-based prospective survey of AF patients who visited the 
participating medical institutions in Fushimi-ku, Japan. We investigated the clinical characteristics and 
outcomes of asymptomatic versus symptomatic patients in the paroxysmal (n=1,837) and 
persistent/permanent (as sustained: n=1,912) AF subgroups.  
Results: In the paroxysmal AF (PAF) group, asymptomatic patients were older (asymptomatic vs. 
symptomatic: 74.1 vs. 71.1 years of age; p<0.01), more often male (62.1% vs. 55.6%; p<0.01), and had a 
higher CHA2DS2-VASc score (mean 3.37±1.73 vs. 2.99±1.63; p<0.01), while the prevalence of major 
comorbidities and CHA2DS2-VASc scores were comparable in the sustained AF (SAF) group. Multivariable 
analysis indicated that age (≥75 years), history of stroke/SE, male sex, and chronic kidney disease were 
independent determinants of asymptomatic status in the PAF group, while age was non-significant in the 
SAF group. During the follow-up period, all-cause mortality was significantly higher (hazard ratio [HR], 1.71; 
95% confidence interval [CI], 1.31-2.29; p<0.01) in asymptomatic patients compared with symptomatic 
patients in the PAF group, while it was comparable in the SAF group.  
Conclusions: Asymptomatic clinical status is associated with older age, males, more co-morbidities with 
higher stroke risk profile, and a higher incidence of all-cause death in patients with PAF, whereas these 
characteristics and outcomes were not seen in the SAF group.  
 
Clinical Trial Registration: URL: http://www.umin.ac.jp/ctr/index.htm 
Unique identifier: UMIN000005834. 
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Introduction 
Detection and diagnosis of atrial fibrillation (AF) can be challenging in patients who are asymptomatic or 
minimally symptomatic, regardless of whether it is paroxysmal or persistent/permanent.1 Undiagnosed 
asymptomatic AF is important and may lead to a first presentation with acute ischaemic stroke or 
decompensated heart failure.2  
Several studies have compared the clinical characteristics and outcomes in asymptomatic and symptomatic 
AF patients; however, the majority of patients in these studies had persistent or permanent AF, and were 
reported from Western population cohorts.3-5 There are limited data on differences in the clinical 
characteristics and outcomes of community-based asymptomatic AF patients with paroxysmal and 
persistent/permanent AF, particularly from Asian cohorts.   
The aim of this study was to investigate the clinical profile and outcomes of asymptomatic AF patients, when 
compared with symptomatic patients, with paroxysmal and sustained (i.e. persistent/permanent) AF from the 
Fushimi AF registry, a community-based prospective survey of Japanese patients with AF.6-8 
 
Methods 
Study Cohort 
The detailed study design, patient enrollment, the definition of measurements, and subjects’ baseline clinical 
characteristics in the Fushimi AF Registry were previously described (UMIN Clinical Trials Registry: 
UMIN000005834).6 The inclusion criterion for the registry is the documentation of AF on a 12-lead ECG or 
Holter monitoring at any time. There are no exclusion criteria. Patient enrollment was started in March 2011. 
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and was 
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approved by the ethics committees of the National Hospital Organization Kyoto Medical Center and Ijinkai 
Takeda General Hospital. 
 
Cohort Classification 
The entire cohort was divided into two subgroups of AF defined as follows: (i) Paroxysmal AF (PAF), defined 
as self-terminating episodes lasting less than 7 days; and (ii) Sustained AF (SAF), defined as either 
persistent (episodes lasting longer than 7 days which can be terminated either by pharmacological therapy 
or electric cardioversion) or permanent (AF that is accepted by the patient (and physician), for which rhythm 
control interventions are not pursued) AF.9,10 The patients were subsequently differentiated as being either 
asymptomatic or symptomatic at the time of enrollment based on their physicians' diagnosis and/or 
discretion. The symptoms of each patient were broadly described as one of the following: palpitations, 
orthopnea, fatigue, chest pain, and faintness; and patients were categorized into asymptomatic when the 
patient did not have any symptoms. The baseline characteristics and clinical outcomes of asymptomatic and 
symptomatic AF patients were compared in the PAF and SAF groups. 
 
Study Endpoints 
The clinical endpoints in this analysis were the incidence of stroke/SE, all-cause mortality, heart failure (HF) 
admission, and major bleeding during the follow-up period. These endpoints were also analyzed in the 
subgroups stratified by OAC use at baseline. OACs included warfarin, dabigatran, rivaroxaban, apixaban, 
and edoxaban. Stroke was defined as the sudden onset of a focal neurologic deficit in a location consistent 
with the territory of a major cerebral artery, and the diagnosis of ischemic or hemorrhagic stroke was 
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confirmed by computed tomography or magnetic resonance imaging. SE was defined as an acute vascular 
occlusion of an extremity or organ. Major bleeding was defined as a reduction in the hemoglobin level of ≥2 
g/dl, transfusion of ≥2 units of blood, or symptomatic bleeding in a critical area or organ. HF was defined by 
clinical symptoms and signs, with a comprehensive examination to confirm the underlying cardiac disorder.  
 
Statistical Analyses 
Continuous variables are expressed as mean ± standard deviation (SD) or median and interquartile range 
(IQR). Categorical variables are presented as numbers and percentages. We compared categorical 
variables using the chi-square test when appropriate; otherwise, we used the Fisher’s exact test. The 
Kaplan-Meier method was used to estimate the cumulative incidence of each clinical event. We conducted a 
multivariable analysis using a logistic regression method to investigate the independent determinants of 
asymptomatic clinical status. The covariates chosen to be included in model were male sex, coronary artery 
disease, chronic kidney disease (CKD; persistent proteinuria or estimated glomerular filtration 
rate<60ml/min/1.73m2),11 and components of the CHA2DS2-VASc risk score (congestive heart failure, 
hypertension, age≥75 years, diabetes mellitus, history of stroke, vascular disease, age 65-74 years and 
female sex).12 A multivariable Cox proportional hazard model was used to calculate the hazard ratios (HRs) 
of asymptomatic status for major clinical events in the PAF patients. Covariates chosen to be included in the 
model were age, body weight, history of stroke/SE, history of heart failure, hypertension, diabetes mellitus, 
coronary artery disease, peripheral artery disease, CKD, and history of major bleeding.  
Data were analyzed with the use of the online software, ‘EZR’ (Easy R 32-bit version; 
http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmed.html), for Windows.13 A two-sided P-value<0.05 
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was considered statistically significant. onfidence intervals (CI) are reported as 95%. 
 
Results 
A total of 4,484 patients were enrolled by the end of December 2015. Of the 4,185 patients who were 
enrolled 1 year prior (by the end of December 2014), follow-up data (collected every year) were available for 
3,749 patients (follow-up rate: 89.6%). Of these 3,749 patients, 1,971 patients (52.6%) were asymptomatic, 
and the remaining 1,778 (47.4%) patients were symptomatic; 1,837 patients (49%) had PAF and 1,912 
patients (51%) had SAF. Furthermore, 689 patients (37.5%) and 1,282 patients (67.1%) were asymptomatic 
in the PAF and SAF group, respectively. Median follow-up was 1,099 days (IQR 479–1719 days).  
 
Baseline Clinical Characteristics 
Mean (±SD) age and CHA2DS2-VASc score in the entire cohort were 73.6 (±11) years, and 3.37 (±1.7), 
respectively. Asymptomatic patients were older, and had a higher mean CHA2DS2-VASc score than 
symptomatic patients in the entire cohort (asymptomatic vs. symptomatic: 74.7 (±10.6) vs. 72.4 (±11.3); 
P<0.01, and 3.49 (±1.72) vs. 3.23 (±1.68); P<0.01, respectively).  
Baseline clinical characteristics of asymptomatic and symptomatic patients in both the PAF and SAF groups 
are summarized in Table 1. In the PAF group, asymptomatic patients were more often male, older, and were 
more likely to have a history of stroke/SE, CKD, and major bleeding. Both the mean CHADS2 and 
CHA2DS2-VASc scores were higher in asymptomatic patients. There was less use of class I antiarrhythmic 
drugs (AAD), and β-blockers in the asymptomatic patients compared with symptomatic ones, whereas the 
OAC use was similar. In the SAF group, asymptomatic patients were often male and were more likely to 
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have a history of stroke/SE, but the mean CHADS2 and CHA2DS2-VASc scores were similar. There was a 
lower rate of class I antiarrhythmic drug (AAD), β-blocker, and diuretics use in asymptomatic patients. The 
use of OACs was also lower in asymptomatic patients than in symptomatic patients. A lower proportion of 
asymptomatic patients underwent invasive catheter ablation compared with symptomatic patients in both 
PAF and SAF groups.  
On multivariable logistic regression analysis, male sex, age (≥75 years), CKD, history of stroke/SE, and 
major bleeding were significantly associated with asymptomatic status in the PAF group, after adjusting for 
several covariates including the components of the CHA2DS2-VASc score (Table 2). In the SAF group, the 
same covariates as in the PAF group, with the exception of age, were also significantly associated with 
asymptomatic status.    
 
Clinical Outcomes      
Major clinical events in the PAF or SAF group and in the entire cohort during the follow-up period are shown 
in Table 3. Kaplan-Meier curves for the incidences of stroke/SE, all-cause mortality, HF admission, and 
major bleeding are shown in Figure 1 (PAF group) and Figure 2 (SAF group).  
In the PAF group, all-cause mortality was significantly higher in asymptomatic patients compared with 
symptomatic patients (asymptomatic versus symptomatic: 7.25 versus 3.70 per 100 person-years; P<0.01, 
Table 3). The mortality between asymptomatic PAF group and the entire SAF group was non-significantly 
different (7.25 versus 6.67 per 100 person-years; P=0.11). All the other outcomes (stroke/SE, HF admission, 
and major bleeding) were non-significantly different between asymptomatic and symptomatic patients in 
PAF.  
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On multivariable analysis, asymptomatic status was significantly associated with the higher mortality in PAF 
patients after adjusting for potential confounders (HR, 1.71; 95% CI, 1.31-2.29; P<0.01) (Table 4). The 
higher risk of mortality persisted even when the PAF patients were stratified by OAC status (With OAC: HR, 
1.74; 95% CI, 1.12-2.71, Without OAC: HR, 1.68; 95% CI, 1.20-2.34) (Table 4). All clinical outcomes were 
non-significantly different between asymptomatic and symptomatic patients in the SAF group (Table 3).   
Finally, we explored the risk factors of all-cause death in the PAF patients, using multivariable logistic 
regression analysis. As shown in the Table 5, after adjusting for confounders, asymptomatic status was an 
independent risk factor of the incidence of all-cause death during the follow-up period in the PAF group (HR: 
1.73, 95% CI: 1.29-2.33; P<0.01). 
 
Discussion 
In this large community-based Asian cohort from Japan comparing characteristics and outcomes between 
paroxysmal and sustained AF patients in relation to symptomatic status, our principal findings are as follows: 
(i) asymptomatic patients have more comorbidities with higher CHADS2 and CHA2DS2-VASc scores, a 
higher incidence of all-cause death compared with symptomatic patients in the PAF group, whereas these 
characteristics and outcomes were not seen in the SAF group; (ii) independent determinants of 
asymptomatic presentation were male sex, age, CKD, and prior history of stroke/SE or major bleeding in the 
PAF group, but not age in the SAF group; and (iii) all-cause mortality was higher in asymptomatic patients 
compared to symptomatic patients in the PAF group, with asymptomatic clinical status being an independent 
risk factor for all-cause mortality.  
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Clinical profile of asymptomatic patients  
Asymptomatic AF is common in daily “real-world” clinical practice14-16. However, the relationship between 
patient characteristics and symptom presentation has not been consistent across studies and therefore 
remains controversial. Additionally, these relationships have not been studied in community-based PAF and 
SAF groups, nor in Asian AF cohorts.  
In the present study, we show distinct clinical characteristics of asymptomatic and symptomatic patients in 
the PAF group, rather than those in the SAF group. There were more comorbidities with higher CHADS2 and 
CHA2DS2-VASc scores in asymptomatic patients than in symptomatic in the PAF group, while these were 
similar in the SAF group; however, asymptomatic PAF and SAF patients have similar risks of 
thromboembolism. The proportions of invasive and medical treatments were similar or less frequent in 
asymptomatic patients compared with symptomatic patients in both the PAF and SAF groups, indicating that 
the symptomatic status is likely to affect the physicians' decision on treatment strategy in both PAF and SAF 
patients. 
Male sex, CKD, and history of stroke/SE or major bleeding were significantly associated with asymptomatic 
status both in the PAF and SAF group. The higher prevalence of asymptomatic status in male was 
consistent with previous reports. 17 Nonetheless, we recognize that CKD and previous stroke/SE or major 
bleeding may be related to physical disability and/or inactivity, which could make patients asymptomatic. 
 
Clinical outcomes of asymptomatic patients in the paroxysmal and sustained AF groups 
In the present study, all-cause mortality was higher in asymptomatic than symptomatic patients, but only in 
the PAF group. In a study by Boriani et al.,3,15 asymptomatic patients were associated with more 
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comorbidities, higher CHA2DS2-VASc score, and had higher mortality, compared with symptomatic patients. 
They therefore concluded that asymptomatic AF is not benign but is associated with a higher mortality risk, 
inconsistent with prior randomized clinical trials.5,18 Our present data also demonstrate worse clinical 
outcomes of asymptomatic patients compared with those of symptomatic patients in the PAF group, but not 
in the SAF group. One possible reason of these distinct outcomes between the PAF and SAF subgroups 
may be due to the difficulty of AF detection in patients with PAF compared with SAF. SAF can be easily 
detected with routine ECG even in the absence of symptoms, but PAF would be less easily detected, 
especially if asymptomatic. Hence, optimal AF management would be delayed or inappropriate, including 
OAC treatment. Indeed, asymptomatic patients were older, with more comorbidities and higher 
CHA2DS2-VASc score compared with symptomatic patients in the PAF group, perhaps because those 
patients were more likely to be undetected. In contrast, differences between asymptomatic and symptomatic 
patients were not observed in SAF group, which suggests similarity of AF detection irrespective of patients’ 
symptoms. 
Recent studies have reported that the patients with PAF had a lower rate of stroke/SE or mortality than those 
with SAF.19,20 However, our present findings suggest that these outcomes were not applicable in terms of the 
asymptomatic clinical status. Our present study highlights the worse outcomes of asymptomatic PAF 
patients, that are comparable to those in patients with SAF, thus emphasizing the importance of early AF 
detection and holistic management in daily cardiology practice.       
 
Limitations 
Several limitations should be acknowledged in interpreting the results of the present study. First, the results 
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are derived from an observational study, and describes associative, not causative evidence. The present 
data were derived from an urban district in Japan, and therefore the results cannot be easily extrapolated to 
other rural areas, countries, or population-based registries. Second, OAC data were collected only at the 
time of study entry, so we could not examine the relationship between changes in OACs and clinical events. 
Additionally, the type of antithrombotic drugs and doses were selected at the discretion of the attending 
physician. Third, we did not investigate the time in therapeutic range for patients receiving warfarin during 
follow-up or the adherence to OAC therapies. Therefore, it is difficult to determine the influence of the quality 
of warfarin control and the adherence of OAC therapies on outcomes. Fourth, we were unable to assess AF 
burden, which might have affected the incidence of stroke/SE in patients with PAF. Fifth, the diagnosis of the 
type of AF, the determination of symptomatic/asymptomatic status and the classification of symptoms were 
physician-dependent at the time of enrollment, which may affect the clinical profiles and outcomes. Moreover, 
many asymptomatic patients (at enrollment) might have been previously symptomatic, but we did not have 
information on prior symptom status. Indeed, Boriani et al. reported the significant difference in the patient 
characteristics between fully asymptomatic patients and asymptomatic patients with previous symptoms.3 
Sixth, there may be some selection bias for asymptomatic patients: the higher risk profiles might be more 
related to age rather than symptom status, as being older usually represents a longer prior AF duration 
which may potentially leads to an asymptomatic status. Seventh, other minor symptoms which were not 
categorized into any of the five pre-defined symptom types may be overlooked. We unfortunately have no 
data regarding the exercise capacity of asymptomatic patients, which may have a major impact on overall 
outcome. Finally, we cannot rule out the possibility of unmeasured or residual confounding especially with 
age and co-morbidities even after the multivariate analysis. 
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Despite these limitations, our study highlights the differences in the clinical profile and outcomes between 
asymptomatic and symptomatic patients in both the PAF and SAF cohorts. The present data also 
demonstrated that asymptomatic PAF patients may not receive adequate treatment, thus better identification 
and management of such patients with PAF would be needed. 
 
Conclusions 
In this community-based, large prospective cohort of Japanese patients with AF, asymptomatic clinical 
status is associated with older age, males, more co-morbidities with higher stroke risk profile, and a higher 
incidence of all-cause death in patients with PAF, whereas these characteristics and outcomes were not 
seen in the SAF group.  
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Figure Legends 
Figure 1. 
Kaplan-Meier curves for the incidences of stroke/systemic embolism (SE) (A), All-cause death (B), heart 
failure (HF) admission (C), and major bleeding (D) between asymptomatic and symptomatic patients with 
paroxysmal atrial fibrillation. HR indicates hazard ratio; CI, confidence interval. 
Figure 2. 
Kaplan-Meier curves for the incidences of stroke/systemic embolism (SE) (A), All-cause death (B), heart 
failure (HF) admission (C), and major bleeding (D) between asymptomatic and symptomatic patients with 
sustained atrial fibrillation. Abbreviations as in Figure 1.  
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Tables 
 
Table 1. Baseline clinical characteristics, co-morbidities, medical, and invasive treatment   
 PAF (1,837) SAF (1,912) 
 Asymptomatic 
(689) 
Symptomatic 
(1,148) 
P value Asymptomatic 
(1,282) 
Symptomatic 
(630) 
P value 
Baseline characteristics       
Men 428 (62.1%) 638 (55.6%) <0.01 813 (63.4%) 344 (54.6%) <0.01 
Age –yr, mean±SD 74.1±11.5 71.1±11.7 <0.01 75±10 74.7±10.1 0.497 
BMI, mean±SD 22.9±4.1 22.9±3.7 0.692 23±3.8 23.4±4.5 0.099 
Basic heart rate, bpm 77.7±15.9 75.3±15.9 <0.01 79.1±15.1 80.8±17.1 0.037 
LVEF<40% 24/549 (4.4%) 35/919 (3.8%) 0.586 58/1026 (5.7%) 41/456 (9%) 0.024 
LAD (mm), mean±SD 40.1±6.9 40.6±7.1 0.191 47±8.1 47.5±8 0.261 
Symptom type       
palpitation - 921 (80.2%)  - 303 (48.1%)  
orthopnea - 204 (17.8%)  - 300 (47.6%)  
fatigue - 129 (11.2%)  - 174 (27.6%)  
chest pain - 75 (6.5%)  - 32 (5.1%)  
faintness - 105 (9.1%)  - 65 (10.3%)  
Co-morbidities       
CHADS2, mean±SD 2.02±1.36 1.68±1.2 <0.01 2.22±1.38 2.25±1.33 0.72 
CHA2DS2-VASc, mean±SD 3.37±1.73 2.99±1.63 <0.01 3.55±1.71 3.67±1.68 0.14 
History of stroke/SE 158 (22.9%) 138 (12%) <0.01 344 (26.8%) 129 (20.5%) <0.01 
Heart failure 133 (19.3%) 187 (16.3%) 0.112 387 (30.2%) 301 (47.8%) <0.01 
Hypertension 424 (61.5%) 729 (63.5%) 0.425 792 (61.8%) 384 (61%) 0.425 
Diabetes mellitus 173 (25.1%) 243 (21.2%) 0.057 311 (24.3%) 138 (21.1%) 0.134 
Coronary artery disease 119 (17.3%) 188 (16.4%) 0.651 136 (10.6%) 116 (18.4%) <0.01 
Chronic kidney disease 254 (36.9%) 341 (29.7%) <0.01 492 (38.4%) 236 (37.5%) 0.726 
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History of major bleeding 41 (6%) 25 (2.2%) <0.01 64 (5%) 17 (2.7%) 0.021 
Peripheral artery disease 38 (5.5%) 41 (3.6%) 0.057 57 (4.4%) 17 (2.7%) 0.076 
Medical treatment       
OAC at baseline 273 (40%) 472 (41.3%) 0.623 806 (63.2%) 447 (71.1%) <0.01 
Antiplatelet drugs 204 (29.9%) 321 (28.1%) 0.602 358 (28.1%) 173 (27.5%) 0.828 
Class I AAD 145 (21.3%) 397 (34.7%) <0.01 47 (3.7%) 92 (14.6%) <0.01 
Class III AAD 7 (1%) 8 (0.7%) 0.593 3 (0.2%) 3 (0.5%) 0.403 
Bepridil 18 (2.6%) 38 (3.3%) 0.484 12 (0.9%) 8 (1.3%) 0.34 
β-blockers 153 (22.4%) 334 (29.2%) <0.01 340 (26.5%) 245 (38.9%) <0.01 
Calcium antagonists 221 (32.4%) 376 (32.9%) 0.837 380 (29.6%) 179 (28.4%) 0.426 
Digitalis 37 (5.4%) 66 (5.8%) 0.834 251 (19.6%) 107 (17%) 0.202 
Diuretics 156 (22.9%) 217 (19%) 0.048 416 (32.6%) 261 (41.5%) <0.01 
Invasive treatment       
Catheter ablation 28 (4.1%) 133 (11.6%) <0.01 21 (1.6%) 50 (7.9%) <0.01 
 
Categorical data are presented as number (%). Continuous data are presented as mean ± standard 
deviation (SD). PAF: paroxysmal atrial fibrillation, SAF: sustained atrial fibrillation, BMl: body mass index, 
LVEF: left ventricular ejection fraction, LAD: left atrial diameter, SE: systemic embolism, OAC: oral 
anticoagulants, AAD: antiarrhythmic drug. 
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Data are presented as OR (odds ratio) and 95% CI (confidence interval). 
PAF: paroxysmal atrial fibrillation, SAF: sustained atrial fibrillation, SE: systemic embolism. 
 
Table 2. Indicators of the asymptomatic clinical status – Multivariable Analysis 
 PAF  SAF 
Variable OR 95% CI P value OR 95% CI P value 
Heart failure 1.10 0.85-1.44 0.47  0.48 0.39-0.59 <0.01 
Hypertension 0.87 0.71-1.07 0.18  1.03 0.84-1.26 0.81 
Age (≥75 years) 1.31 1.07-1.60 <0.01  1.04 0.85-1.28 0.70 
Diabetes mellitus 1.18 0.94-1.50 0.16  1.22 0.96-1.55 0.11 
History of stroke/SE 1.90 1.46-2.46 <0.01  1.35 1.06-1.72 0.016 
History of major bleeding 2.09 1.24-3.54 <0.01  1.93 1.09-3.41 0.024 
Male sex 1.36 1.11-1.66 <0.01  1.39 1.13-1.70 <0.01 
Coronary artery disease 0.90 0.69-1.18 0.46  0.52 0.39-0.69 <0.01 
Chronic kidney disease 1.26 1.02-1.57 0.035  1.35 1.09-1.68 <0.01 
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Data are presented as incidence rates (per 100 person-years). P value for comparison between 
asymptomatic versus symptomatic using a log-rank test. 
PAF: paroxysmal atrial fibrillation, SAF: sustained atrial fibrillation, SE: systemic embolism, HF: heart  
failure. 
 
 
 
 
Table 3. Incidence of clinical events during follow-up (/100 person-years) 
 
PAF  SAF 
Outcomes Incidence rate P value 
 
Incidence rate P value 
Stroke/SE 1.79   2.59  
Asymptomatic 2.06 0.069  2.82 0.087 
Symptomatic 1.63   2.13  
All-cause death 5.03   6.67  
Asymptomatic 7.25 <0.01  7.04 0.076 
Symptomatic 3.70   5.92  
HF admission 2.33   4.35  
Asymptomatic 2.27 0.65  3.96 0.08 
Symptomatic 2.37   5.15  
Major bleeding 1.66   1.87  
Asymptomatic 1.89 0.087  1.77 0.59 
Symptomatic 1.53   2.07  
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Data are presented as HR (hazard ratio) and 95% CI (confidence interval). 
HR was adjusted by age, body weight, history of stroke/SE, history of heart failure, hypertension, diabetes 
mellitus, coronary artery disease, peripheral artery disease, chronic kidney disease, and history of major 
bleeding.  
PAF: paroxysmal atrial fibrillation, SE: systemic embolism, HF: heart failure, OAC: oral anticoagulants. 
 
 
Table 4.  Relative risk of asymptomatic status for major clinical events in the PAF patients  
- Multivariable Analysis  
 Entire Cohort  With OAC  Without OAC 
 HR 95% CI P value  HR 95% CI P value  HR 95% CI P value 
Stroke/SE 1.28 0.82-2.01 0.28 1.05 0.52-2.11 0.90  1.46 0.79-2.71 0.23 
All-cause death 1.71 1.31-2.29 <0.01 1.74 1.12-2.71 0.013  1.68 1.20-2.34 <0.01 
HF admission 0.96 0.65-1.44 0.86 1.19 0.71-2.00 0.78  0.78 0.42-1.46 0.44 
Major bleeding 1.18 0.74-1.90 0.48 1.57 0.77-3.20 0.21  0.93 0.48-1.79 0.83 
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Data are presented as OR (odds ratio) and 95% CI (confidence interval). 
PAF: paroxysmal atrial fibrillation, SE: systemic embolism, OAC: oral anticoagulants. 
 
 
 
 
 
 
Table 5. Risk factors of all-cause death in the PAF patients  
– Multivariable Analysis 
Variable OR 95% CI P value 
Asymptomatic status 1.73 1.29-2.33 <0.01 
Heart failure 2.77 1.99-3.86 <0.01 
Hypertension 0.80 0.59-1.08 0.15 
Age (≥75 years) 2.56 1.86-3.53 <0.01 
Diabetes mellitus 1.42 1.02-1.97 0.039 
History of stroke/SE 1.95 1.36-2.80 <0.01 
Male sex 1.24 0.92-1.68 0.16 
Coronary artery disease 1.17 0.82-1.68 0.38 
Chronic kidney disease 2.10 1.54-2.85 <0.01 
History of major bleeding 2.09 1.15-3.81 0.015 
OAC use 0.59 0.43-0.80 <0.01 
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e-Appendix 1.   
Working Group Members 
The following is a list of the institutions participating in the registry. 
Chief investigator: Akao M (National Hospital Organization Kyoto Medical Center). 
Vice-chief investigator: Chun YH (Ijinkai Takeda General Hospital).  
Steering Committee: Esato M (Ijinkai Takeda General Hospital), Abe M (National Hospital 
Organization Kyoto Medical Center), Tsuji H (Tsuji Clinic), Furuke K (Furuke Clinic). 
Statistical Analysis: Wada H (National Hospital Organization Kyoto Medical Center). 
Coordinator: Ogawa T (Ogawa Medical Office), Tasato H (Tasato Clinic), Taniguchi Y (Taniguchi 
Clinic), Nishikawa M (Nishikawa Clinic), Furukawa K (Furukawa Medical Clinic), Kawai C, Hashimoto 
T, Kanda M (Ijinkai Takeda General Hospital), Tsukahara T, Fukuda S, Nakamura M, Ohtani R, Ito 
T, Hasegawa K (National Hospital Organization Kyoto Medical Center). 
Clinical Event Committee: Kawabata Y, Yasuda K, Kameyama K (National Hospital Organization 
Kyoto Medical Center). 
Participating institutions: Department of Cardiology, National Hospital Organization Kyoto 
Medical Center (Akao M, Abe M, Ogawa H, Masunaga N, Iguchi M, Ishii M, An Y, Unoki T, Niki S, 
Takabayashi K, Hamatani Y, Yamashita Y, Takagi D, Tezuka Y, Doi K, Aono Y, Ikeda S, Osakada G, 
Nakashima Y, Kanasaki M, Nakano T, Funatsu J, Nishio M, Takenaka Y); Department of Arrhythmia, 
Ijinkai Takeda General Hospital (Chun YH, Esato M, Kida Y, Nishina N); Koujinkai Oshima Hospital 
(Terada K); Division of Translational Research, National Hospital Organization Kyoto Medical Center 
(Hasegawa K, Wada H); Kanai Hospital (Nishio M, Kamiya Y, Abe M, Ishii M); Tsuji clinic (Tsuji H); 
Furukawa Medical Clinic (Furukawa K); Nishikawa Clinic (Nishikawa M); Taniguchi Clinic (Taniguchi 
Y); Gushiken Clinic (Gushiken T); Kyoto Rehabilitation Hospital (Hirata Y); Yoda Clinic (Yoda J); 
Tasato Clinic (Tasato H); Ogawa Medical Office (Ogawa T); Mukaijima Hospital (Wakatsuki Y, 
Yahata M, Higashitani N); Itoh Hemodialysis Clinic (Itoh H); Itoh Clinic (Itoh H, Ohmori Y); 
Ryokuhoukai Tsuji Clinic (Tsuji K); Kitamura Clinic (Kitamura S); Izumikawa Clinic (Izumikawa F); 
Hirota Clinic (Hirota N); Kyomachi-Oota Clinic (Oota K); Kouseikai Rehabilitation Clinic (Kou K); 
Inariyama Takeda Hospital (Tanaka T, Iguchi M); Matsushita Clinic (Matsushita N); Kitani Clinic 
(Kitani K); Kimura Clinic (Kimura F); Hayashi Clinic (Hayashi S); Handa Clinic (Handa S); Soseikai 
General Hospital (Hasegawa S, Kono T, Otsuka K, Soyama A, Okamoto J, Nakai Y); Asamoto Clinic 
(Asamoto H); Sugano Clinic (Tanaka H, Murata T); Fushimi Momoyama General Hospital 
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(Kayawake S, Kinoshita Y); Furuke Clinic (Furuke K); Kanehisa Clinic (Asano N); Tahara Clinic 
(Tahara K); Matsumoto Medical Office (Matsumoto K); Kuroda Clinic (Kuroda O); Ochiai Clinic 
(Ochiai K, Ochiai J); Fujii Clinic (Fujii M); Kurihara Clinic (Kurihara M); Kuzuyama Clinic (Ito A); 
Kenkokai Fushimi Clinic (Totsuzaki S); Nakayama Orthopedic Clinic (Nakayama H); Department of 
Cardiovascular Medicine, Ijinkai Takeda General Hospital (Kawai C, Hashimoto T, Kakio T, 
Watanabe C, Takeda S, Sasaki Y, Shirasawa K, Beppu K, Inoue T, Shirasaka A, Doi T); Tatsumi 
Clinic (Ueda T); Oishi Clinic (Oishi M); Koizumi Clinic (Kasahara A); Kishida Clinic (Kishida Su, 
Kishida Sa); Shibata Clinic (Shibata M); Shimizu Clinic (Shimizu J); Shirasu Clinic (Shirasu M); 
Fujinokai Clinic (Tateishi S); Tsukuda Clinic (Tsukuda N); Shinseikai Tsuji Clinic (Tsuji K); Nishi 
Clinic (Nishi T); Nishimura Clinic (Nishimura S); Haba Clinic (Haba T); Higashimae Clinic 
(Higashimae R); Fujimori Clinic (Fujimori C); Hotta Clinic (Hotta T); Matsui Clinic (Matsui H, Matsui 
H); Shadan Matsumoto Clinic (Matsumoto H); Maruo Clinic (Maruo N); Misu Clinic (Mikami M); 
Mekata Clinic (Mekata H); Mori Pediatric Clinic (Mori H); Wakabayashi Clinic (Wakabayashi M); 
Nakatsugawa Clinic (Sasaki Z); Shiseikai Nishimura Clinic (Nishimura S); Yuge Eye Clinic (Yuge K); 
Gokita Hospital (Haruta M); Soseikai Clinic (Tsuda E); Toujinkai Hospital (Nishimura M); Kouno 
Clinic (Kouno T, Kouno Y); Matsumura Clinic (Matsumura S); Fujita Clinic (Fujita A); Takayasu 
Clinic (Takayasu F, Takayasu S), Yano Clinic (Yano Y), Niki Clinic (Niki S), Hasegawa Meiando Clinic 
(Hasegawa S), Watanabe Medical Clinic (Watanabe T). 
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